PDS Biotechnology Corp Deferred Offering Costs
PDS Biotechnology Corp (PDSB) had Deferred Offering Costs of $0 as of 2015-12-31, per its 10-K filed 2016-03-08.
Discontinued › Balance Sheet › Assets
us-gaap:DeferredOfferingCosts · last filed 2016-03-08
- 2015-12-31: Deferred Offering Costs $0.00.
- 2015-09-30: Deferred Offering Costs $2.38M.
- 2014-12-31: Deferred Offering Costs $1.41M.
| Period end | Deferred Offering Costs |
|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-03-08 |
| 2015-09-30 | $2.38M 10-Q · filed 2015-11-06 |
| 2014-12-31 | $1.41M 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |